Report Urges Mexico to Address Liver Health in Programs
A new report suggests that Mexico should integrate liver health screening into existing public health programs for diabetes and obesity. Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in Mexico and is a leading cause of cirrhosis.
Why it matters
Addressing liver health as part of broader metabolic disease management could significantly improve public health outcomes and reduce mortality rates in Mexico.
Liver disease may affect close to half of adults in Mexico, yet the country tracks it far less closely than the diabetes and obesity to which it is linked, according to a new paper by Jeffrey Lazarus , professor at the CUNY Graduate School of Public Health and Health Policy Professor (CUNY SPH) , and colleagues, and released to coincide with the International Congress on Obesity taking place in Mexico City this week. The authors argue Mexico should fold liver health into its existing programs for diabetes, obesity, and other noncommunicable diseases rather than treating it as a separate problem.
The article reports on public health research and policy recommendations without ideological slant.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in